Table 1.

Demographic, BP, and echocardiographic data for ARVD and control groups^a

	ARVD		P^b	AOR (95% CI)^c of ARVD	P^d
	No (n = 50)	Yes (n = 79)	P^b	AOR (95% CI)^c of ARVD	P^d
Age (yr)	69 ± 9	71 ± 7	NS	1.04 (0.98 to 1.10)	0.2
Gender					0.9
male	38.0%	58.2%	NS	1
female	62.0%	41.8%		0.93 (0.37 to 2.32)
Diabetes	30.0%	24.1%	NS	0.81 (0.30 to 2.18)	0.7
Ischemic heart disease	22.0%	32.9%	NS	1.56 (0.55 to 4.42)	0.4
eGFR (ml/min)	33 ± 16	36 ± 19	NS	1.01 (0.98 to 1.03)	0.8
24-h urinary protein (g/d)	1.4 ± 2.0	0.4 ± 0.5	<0.001	0.21 (0.07 to 0.62)	0.005
24-h systolic BP (mmHg)	138 ± 17	140 ± 19	NS	1.02 (1.00 to 1.05)	0.07
24-h diastolic BP (mmHg)	75 ± 12	73 ± 13	NS	1.00 (0.96 to 1.04)	0.9
Hemoglobin (g/L)	124 ± 18	127 ± 20	NS	0.99 (0.97 to 1.02)	0.6
LV hypertrophy	46.0%	78.5%	<0.001	5.54 (2.04 to 15.02)	0.001
LVMI (g/m²)	116 ± 33	183 ± 74	<0.001	1.04 (1.02 to 1.05)^f	<0.001
LVEF (%)	57 ± 12	53 ± 12	NS	0.97 (0.94 to 1.01)	0.16
LVEDV index (ml/m²)	34 ± 16	82 ± 35	<0.001	1.18 (1.09 to 1.28)	<0.001
Two or more LV diastolic function abnormalities^e	12.0%	40.5%	<0.001	16.3 (3.9 to 68.5)	0.001

↵^a AOR, adjusted odds ratio; ARVD, atherosclerotic renovascular disease; CI, confidence interval; eGFR, estimated GFR; LV, left ventricular; LVH, LV hypertrophy; LVMI, LV mass index; LVEF, LV ejection fraction; LVEDV, LV end-diastolic volume.
↵^b Compared using the χ² test for categorical variable and ANOVA test for continuous variables.
↵^c Using multiple logistic regression, with the presence (coded 1) or absence (coded 0) of ARVD as the dependent variable and adjusted for age, gender, diabetes, ischemic heart disease, eGFR, 24-h urinary protein, 24-h systolic BP, and hemoglobin.
↵^d Adjusted for age, gender, diabetes, ischemic heart disease, eGFR, 24-h urinary protein, and hemoglobin.
↵^e Categories were combined because no patient in the control group had three diastolic function abnormalities.
↵^f Each 1-g/m² increment in LVMI is associated with a 4% increment in the AOR of ARVD.